ISRG's SP Platform: Early-Stage Growth or Next TAM Expansion Driver?
ISRG's SP platform sees Q1 2026 procedures jump 68%, with new approvals and tools raising a key question: TAM expansion or procedure shift?
More News
Abbott's Biosimilar Push to Help Sustain EPD Growth Momentum
ABT's EPD unit posts 9% Q1 sales growth as biosimilars and emerging market demand support its long-term expansion plans.
Silver Economy Investing: Why the Healthcare Giants Are in Focus
Healthcare giants like Eli Lilly, Tandem Diabetes, Intuitive Surgical and ResMed are tapping aging-driven demand in obesity, surgery and sleep care.
Boston Scientific Bets on Growth Through Strategic M&A Deals
BSX expands into fast-growing medtech segments with acquisitions spanning urology, pain management and vascular devices.
ABT vs. ZBH: Which Surgical Equipment Stock Is the Better Bet Now?
Abbott vs. Zimmer Biomet: surgical equipment stocks face diverging growth, acquisitions, and valuation shifts as investors weigh momentum and margins.
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
How Abbott's Volume-Driven Nutrition Strategy Is Shaping Up
ABT shifts to a volume-led Nutrition strategy with pricing moves and new product launches after Q1 sales declined 6%.
Jim Cramer Compares the Current Selloff in Abbott Labs to the 1999 Market Environment
Jim Cramer Compares the Current Selloff in Abbott Labs to the 1999 Market Environment...
Should You Buy, Hold or Sell BSX Stock Amid Cardiovascular Boom?
Boston Scientific rides on cardiovascular device growth with FARAPULSE and WATCHMAN momentum, but margin pressure and weaker estimates cloud the outlook.
Abbott Stock at 52-Week Low After Q1 Earnings: Book Profits or Hold?
ABT's Q1 beat was overshadowed by Exact Sciences dilution, legal risks and weak Diagnostics trends as shares hit a 52-week low.